Researchers at the University of Michigan helped develop a newly approved therapy for a hard-to-treat form of acute myeloid leukemia, marking a major step forward for patients with NPM1-mutant disease. Their work with industry partners moved a scientific discovery from the lab into a real treatment now available to those in need. Ongoing studies are exploring how the therapy may be used more broadly in the future.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.